Medical resource utilization among patients with ventilator-associated pneumonia: Pooled analysis of randomized studies of doripenem versus comparators

Critical Care

Volumn 14, Issue 3, 2010, Pages

  Kollef, Marin H ^a   Nathwani, Dilip ^b,f   Merchant, Sanjay ^c   Gast, Christopher ^d,e   Quintana, Alvaro ^c   Ketter, Nzeera ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Infection Unit   (United Kingdom)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d Axio Research Corporation   (United States)

^e Private Consultant   (United States)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; FEMALE; FISHER EXACT TEST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANK SUM TEST; SINGLE DRUG DOSE; VENTILATOR ASSOCIATED PNEUMONIA; AGED; ECONOMICS; HEALTH CARE PLANNING; LENGTH OF STAY; MIDDLE AGED; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEALTH RESOURCES; HUMANS; IMIPENEM; LENGTH OF STAY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77951963695     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9012     Document Type: Article

References (30)

1. Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004, 25:1090-1096. 10.1086/502349, 15636298.
2. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33:2184-2193. 10.1097/01.CCM.0000181731.53912.D9, 16215368.
3. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31:1312-1317. 10.1097/01.CCM.0000063087.93157.06, 12771596.
4. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159:1249-1256.
5. Vidaur L, Planas K, Sierra R, Dimopoulos G, Ramirez A, Lisboa T, Rello J. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 2008, 133:625-632. 10.1378/chest.07-2020, 18198250.
6. Bou R, Lorente L, Aguilar A, Perpinan J, Ramos P, Peris M, Gonzalez D. Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections. J Hosp Infect 2009, 71:138-142. 10.1016/j.jhin.2008.07.018, 18799237.
7. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27:893-900. 10.1086/507274, 16941312.
8. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008, 52:813-821. 10.1128/AAC.01169-07, 2258516, 18070961.
9. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009, 37:1463-1469. 10.1097/CCM.0b013e31819ced02, 19242341.
10. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996, 22:387-394. 10.1007/BF01712153, 8796388.
11. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268. 10.1378/chest.122.1.262, 12114368.
12. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420. 10.1378/chest.113.2.412, 9498961.
13. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685. 10.1378/chest.111.3.676, 9118708.
14. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:196-200.
15. Luna CM, Aruj P, Niederman MS, Garzon J, Violi D, Prignoni A, Rios F, Baquero S, Gando S. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006, 27:158-164. 10.1183/09031936.06.00049105, 16387949.
16. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. 10.1164/rccm.200405-644ST, 15699079.
17. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005, 52:71-74. 10.1016/j.diagmicrobio.2004.12.008, 15878447.
18. Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008, 24:2113-2126. 10.1185/03007990802179255, 18549664.
19. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096. 10.1097/CCM.0b013e3181691b99, 18379232.
20. Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008, 30:717-733. 10.1016/j.clinthera.2008.04.001, 18498921.
21. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003, 31:676-682. 10.1097/01.CCM.0000055380.86458.1E, 12626968.
22. Gehan EA. A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 1965, 52:650-653.
23. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2115-2121. 10.1378/chest.122.6.2115, 12475855.
24. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22:89-96. 10.1016/0732-8893(95)00053-D, 7587056.
25. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988, 158:831-847.
26. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005, 49:3944-3947. 10.1128/AAC.49.9.3944-3947.2005, 1195437, 16127078.
27. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 2009, 43:1747-1754. 10.1345/aph.1M304, 19809009.
28. Hofhuis JG, Spronk PE, van Stel HF, Schrijvers GJ, Rommes JH, Bakker J. The impact of critical illness on perceived health-related quality of life during ICU treatment, hospital stay, and after hospital discharge: a long-term follow-up study. Chest 2008, 133:377-385. 10.1378/chest.07-1217, 17925419.
29. Kongnakorn T, Mwamburi M, Merchant S, Akhras K, Caro JJ, Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010, 26:17-24. 10.1185/03007990903358980, 19895363.
30. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159:1127-1132. 10.1001/archinte.159.10.1127, 10335691.